Five New Verigene Studies to be Presented at ICAAC 2015

New clinical data for two Verigene infectious disease tests will be presented during Sepsis Awareness Month at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Diego this week.

The five Verigene studies highlight the performance of the Verigene® Gram-Positive (BC-GP) and Gram-Negative (BC-GN) Blood Culture Test (BC-GN), as well as the clinical impact of rapid testing in combination with antimicrobial stewardship efforts:

Saturday, September 19

  • Comparison Between Nanosphere Verigene BC-GP and PNA FISH Testing on the Treatment of Staphylococcus-related Bloodstream Infections (BSI)
  • Verigene Use in the Management of Patients with Gram Negative Bloodstream Infections
  • Impact of a Rapid Molecular Diagnostic Test and Antimicrobial Stewardship on Time to Optimal Therapy in Bacteremic Patients
  • Outcomes Associated with the Utilization of Rapid Diagnostic Technology and Pharmacist Intervention in the Management of Gram-Negative Bacteremia
  • Sunday, September 20

    • Evaluation of Verigene BC-GN for Identification of Gram Negative Bacteria and Detection of Resistance to Beta-Lactams Including Carbapenems from Solid Media

    ICAAC attendees can stop by booth #429 in the Exhibit Hall to find out what else is new at Nanosphere!